Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If they are paying salary or guarantee well below Industry averages then they must have hefty performance/volume spiffs if they expect their reps to stay energized to produce the outsized results they want. Your comments suggest you have some specialized knowledge in this area so tell me how you would attract and keep quality reps and get the results you want. Do you think Amarin can get those results?
So you believe the company is slow walking the sNDA submission for reasons unknown, whereas I believe the company is preparing their submission expeditiously and it’s way more complicated than you think.
We shall see.
I will repeat the essence of my previous response; to wit, I’m 100% certain the company is not stalling and they will submit the SNDA as quickly as it can be prepared and by that I mean prepared properly to succeed. Nevertheless I suggest you contact IR and ask why it will take so long. I’m also willing to learn that I’m wrong and the company is taking its time.
They can't just put a quarter into the Kinko's copy machine and select an sNDA. Those are very complicated and very long documents that take at least several months to prepare, review, edit, review, correct, review, correct, edit, review, correct, edit, review, etc, before they are ready for submission. In the meantime, business goes on. They are doing a massive sales and marketing ramp-up, presenting at conferences, doing continuing analyses of the RI data, talking to potential partners and strategy consultants and probably fielding early overtures from interested potential buyers. They are delegating much of this but I'm certain they are running a very intense balancing act. I'm also certain that they will not delay the filing one day longer than necessary to get it right, including talking on multiple occasions with the FDA.
A 15% discount at this stage of Amarin's emergence would bring shareholder lawsuits. Maybe 5-6 % max imo. Notice the after hours settled about 6% below the regular close.
If the offering is indeed for $200 million, or about 11 million shares, then after the over-subscription (+15%) it will be $230 million or about 12.6 million shares.
One positive of an offering now is that the shares will likely all go to institutions who want in, raising the institutional interest by a few points.
Dr N is at a minimum a science denier. The further his vested opinion deviates from the evidence the more entrenched he becomes in his alternate reality.
I believe the most significant number yet to come from future data releases will be the per protocol and it could be so astounding as to cause another shockwave in the share price. If I am right, we will never ever again be carborundum’d by the illegitimi.
Thanks. That makes sense because I skimmed through all the abstracts in that issue and the only one that seemed at all relevant was the fatty acid cell signaling article. I did not purchase the pdf download.
Please correct me if I’m wrong. Are you saying that your biochemist/pharmacology professor relative published an article 2 months before the RI topline announcement in Nitric Oxide (pay to read) and that the same article will be available free next June?
What don’t you understand about what BB said? He said you have to pay to read it. It’s a $35 download.
Can you say when the embargo will end and for what publication or presentation the embargo exists?
I don’t mean to discount the fact that Amarin has been selling Vascepa for several years, but the data from Reduce-It are such a game changer as to dwarf the company’s history to this point and to position them as a new force in town.
If Amarin were an established pharma with years of performance history then it would likely be priced based on current performance. But Amarin is not established but rather it is a rapidly growing small pharma emerging from its long status as a development-stage company, so I believe it wnill be priced based on the trajectory of growth. Consequently I expect the price to grow much more in anticipation of the performance that any analyst will be able to see once that trajectory can be seen. I’m not predicting any particular price but I think that $30 6-8 months from now is much too conservative.
Someone with more clout than I have should send that Nissen quack article link (copied below) to herpes and ask him if he’s really interested in the truth.
https://statins.news/2017-08-18-statin-push-quack-steven-nissen-exposed-for-conflicts-of-interest-statin-drug-prostitution-and-science-denialism.html
I really wish we had a rating system. I’d give you 10 stars for that one.
I looked in the mirror and Dr Bhatt was not there.
The good news, JL, is that neither you nor I will have to have the same two teeth extracted again (I had two extractions about two weeks ago).
lI can see some doctors wanting to see that before converting to a EPA fan.
That’s so intriguing you’ve almost got me convinced to get back to active cycling training, competing only with myself of course. Perhaps you saw some of my races when I was younger. They called me Lightning McFerret.
Yes of course the risk for a credentialed person in any area taken by authoring such a work of FUD would be extreme, and if my conjecture were true the named party would’ve taken great care to distance himself from it perhaps by submitting it to a trusted 3rd party, even anonymously, with instructions on how to get it published. When they feel threatened, people will do things they would ordinarily not condone.
In any case I won’t bring it up again.
So you don’t think he’s connected to someone in the press (MH?, AF?) who wanted to get an unfavorable opinion to publish and would trade info? I’m sure that his fear and loathing toward Amarin could push him over the edge because he’s facing a perceived existential threat. Of course it’s just a conjecture on my part and it doesn’t have to be Nissen. I just thought the level of enmity was suggestive.
..."Maybe I'm just like my brother ...".
Hey Chas, I deliberately used the expression in reverse. He makes crap out of gold, or sow's ears out of silk purses, or a small profit from what was a great position.
I strongly expect we’ll be seeing the 9-24 uptick until the AHA uptick overtakes it.
There is nobody on this message board who can make a sow’s ear out of a silk purse better than you. You’re ignoring the evidence and are totally wrong about the LDL change being significant, and it does not reduce the composite RRR to 20%. Why are you spending any time talking to the imitation contractor? He’s not here for rational discourse but rather to disrupt the board. You are his accomplice, cluttering the board with your responses.
I wonder If anyone else agrees with me that DoctRx could very well be Nissen, who hates and fears Amarin.
I would volunteer to give Pyr some “is it safe?” I would give him placebo gas.
It was at the very bottom, the last name when I looked.
Eureka!
https://clinicaltrials.gov/ct2/show/NCT02104817
Principal Investigator: Steven Nissen, MD The Cleveland Clinic
I think if you asked Nissen whether Vascepa causes cancer in rats he would say "Yes but he heard that the sponsor withheld that pre-clinical finding."
I think if you asked Nissen whether Vascepa causes impotence he would say "Yes and I know from personal experience."
Nissen is so threatened by Vascepa that he'd say anything imo.
I think the other so-called experts consulted by the bash bros in the 3 seconds following the embargo lifting are somewhat less qualified than Nissen to render an impartial opinion, due to their multiple conflicts of interest.
Would have had to have been either a Form T or a busted trade methinks.
I just realized that drx is probably Steve Nissen.
Yes they do but not in the individual message view. They show up in the list view. Click on Amarin Corp. ADS (AMRN) link above and you will have the message board list view with the stickies on top.
could you post a complete example, quoting a part of your message in a reply message? -not the result that we would see, but what you would actually type before submitting, maybe using quotes around the expressions that would be interpreted so as to prevent interpretation. The alternative would be me cluttering the board with tests until I get it right.
Great numbers, but unless there’s always some cyclical peak at this time it looks like the RI earthshaking results lifted the competition along with Vascepa.
In a black hole 4 grams would occupy no more volume than a spectk too small for the naked eye to see. In our world we have to deal with this reality: one of the standard relationships that science teaches is that under standard conditions 1 g of water occupies 1 cm³ (cubic centimeter). While oil is slightly less dense than water that would be a good reference point, so, no, the 1 g Vascepa.capsules are not going to get smaller.
And at that point you go to country music and wail about getting your job back, your power back, your money back and your woman back.